Revolution Medicines reported “unprecedented” survival outcomes from its Phase 3 pancreatic cancer study of daraxonrasib, a targeted RAS inhibitor. In the trial, patients receiving daraxonrasib lived a median of 13.2 months versus 6.7 months on standard chemotherapy, and the company said it met key endpoints at an interim checkpoint. Revolution indicated the interim analysis results were statistically significant and clinically meaningful enough that the company ended the trial early and is preparing regulatory steps. The company’s daraxonrasib program had already been granted a “national priority” voucher pilot designation, setting up potential accelerated review dynamics. The readout is intensifying competition in RAS(ON)-directed oncology, particularly for pancreatic ductal adenocarcinoma where durable options remain limited.